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Abstract 
BACKGROUND: Globally, gastric cancer (GC) it is the fourth most common cancer and the third cause of cancer-
related deaths. Overexpression of MDM2 and B-RAF appeared to be increased in malignancy and associated 
with poor prognosis in several human tumours, but their role in gastric cancer remains controversial.  
AIM: We had investigated the immunohistochemical expression of MDM2 and B-RAF in 136 gastric lesions 
with/without H. pylori association. 
MATERIAL AND METHODS: Studied specimens include chronic gastritis (32), intestinal type GC (70), diffuse 
GC (22) and gastrointestinal stromal tumours (GIST) (12).  
RESULTS: MDM2 expression increased significantly in intestinal GC compared to other groups (p < 0.001), while 
B-RAF expression increased significantly in GIST compared to other groups (p < 0.001). H. pylori increased 
expression of MDM2 in intestinal GC cases but did not affect B-RAF expression. MDM2 expression correlated 
with high grade of tumor differentiation (p < 0.001), deep invasion (p < 0.05), nodal metastases (p < 0.05) and 
distant metastases (p < 0.1) in intestinal GC, while B-RAF expression did not correlate with TNM stage (p < 0.1). 
CONCLUSION: MDM2 up-regulation was more frequent in intestinal GC, while B-RAF up-regulation was more 
frequent in GIST compared to other groups; MDM2 expression in intestinal GC was correlated with H. pylori 
association, high grade of differentiation, deep invasion, nodal and distant metastases, meanwhile, B-RAF 
expression was correlated with high-grade intestinal GC but did not correlate with H. pylori or TNM stage. The 
possible role of both MDM2 and B-RAF in predicting progression of gastric tumours and prognosis deserves 
further investigations. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Worldwide, Gastric cancer (GC) is the fourth 
most common cancer in men (8.5%) and the third 
cause of cancer-related deaths (10.1%). In the 
female, it is the fourth most common cancer (4.8%) 
and the third cause of cancer-related deaths (7.2%) 
[1]. Although the incidence of gastric cancer has 
gradually decreased over the last half-century, the 
prognosis of advanced gastric cancer remains poor 
and gastric cancer-related mortality rates remain 
unacceptable in many areas [2].  
Gastric carcinogenesis is a multistep and 
multifactorial process. The intestinal type of gastric 
cancer is often related to environmental factors such 
as Helicobacter pylori infection, diet, and lifestyle, 
while the diffuse type is more often associated with 
genetic abnormalities [3]. 
The Helicobacter pylori (H. pylori) bacterium 
is responsible for 5.5% of all infection-associated 
cancers and is the major cause of gastric cancer in 
consequence of chronic inflammation [4]. Persistent 
gastric mucosa inflammation results in chronic 
gastritis and progresses through a multistep process 
to gastric atrophy, intestinal metaplasia, dysplasia, 
and finally carcinoma [5]. 
In Egypt, infection with H. pylori is common, 
and acquisition of infection occurs at a very young age 
[6]. Also, gastric cancer is the 13
th
 most common 
cancer in men (1.8%) and the 10
th
 cause of cancer-
related deaths (2.2%). In the female, it is the 14
th
 most 
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common cancer (1.5%) and the 11
th
 cause of cancer-
related deaths (2.2%). For both sexes, it is the 12th 
most common cancer (1.6%) and 11
th
 cause of 
cancer-related deaths (2.2%) [7]. 
Several biological markers are tested as 
potential predictors of the gastric carcinoma outcome, 
and some of them are essential to developing a 
malignancy. MDM2 (Murine double minute 2) is an 
oncogene that has been mapped to chromosome 
12q13–14 and encodes a 90 kDa cellular oncoprotein. 
The gene structure on the human chromosome was 
identified in 1992 [8]. It binds to, and negatively 
regulates, transactivation of p53 and was then itself 
found to be a transcriptional target of p53, defining a 
negative feedback loop of p53 tumour suppressor 
gene [9]. The MDM2 oncogene played an important 
role in cancer progression as overexpression of 
MDM2 in tumour cells induced cell proliferation and 
inhibits cell apoptosis [10]. Several studies have 
shown that MDM2 overexpression was associated 
with poor survival and was a useful predictive factor 
for poor prognosis in humans with hepatocellular 
carcinoma and breast carcinomas [11] [12]. 
V-RAF murine sarcoma viral oncogene 
homolog B1 (B-RAF) is a member of the RAF family 
of protein kinases which has three members: A-RAF, 
B-RAF and Raf-1 [13]. All RAF proteins are 
serine/threonine kinases located in the 
RAS/RAF/MEK/ERK cascade as downstream 
effectors of RAS and can phosphorylate and activate 
MEK, which in turn activates ERK. B-RAF is the most 
potent activator of MEK [14] [15] and is the only one 
known to be activated by mutation in human cancer 
[16]. They are mainly found in melanoma, thyroid 
papillary carcinoma and colorectal tumours with 
microsatellite instability [17]. 
In this study, we investigated 
immunohistochemical expression of MDM2 and B-
RAF in chronic gastritis and malignant gastric lesions; 
and their correlation with H. pylori association, tumour 
location, grade, and TNM stage in Egyptian patients. 
 
 
Material and Methods 
 
This study was conducted on 136 archival 
gastric paraffin blocks from Pathology Department of 
Theodor Bilharz Research Institute. All samples had 
been obtained as endoscopic biopsies or gastrectomy 
specimens. The study protocol was approved by the 
Ethics committee of Theodor Bilharz Research 
Institute, for the protection of human subject and 
adopted by the 18
th
 world medical assembly, Helsinki, 
Finland (2013). 
Our studied lesions were classified into four 
groups: chronic gastritis: 32 specimens; intestinal GC: 
70 specimens; diffuse GC: 22 specimens; GIST: 12 
specimens.  
Gastric tissue sections were stained by 
Hematoxylin-eosin for routine diagnosis, grading and 
staging of tumours. Giemsa stain was used to detect 
H. pylori in gastric sections. 
Immunohistochemistry for MDM2 and B-RAF 
was performed on tissue sections cut from the paraffin 
blocks at 4μm onto positively charged slides 
(Superfrost Plus, Menzel-Glaser, Germany) and 
stained on an automated platform (Dako Autostainer 
Link 48) using: anti-human MDM2 monoclonal primary 
antibodies (Clone MSP14, NeoMarkers, Fremont, 
CA, USA) and anti-B-RAF pV600E (Spring 
Bioscience, Pleasanton, CA; purchased from Zytomed 
Systems, Berlin, Germany) at 1:200 dilution. Heat-
induced antigen retrieval was used for 30 min at 97°C 
in the high-PH EnVision™ FLEX Target Retrieval 
Solution.  
For each setting, positive and negative control 
slides were included. As a negative control, gastric 
tissue was processed, but the primary antibodies were 
not added and instead add non-immune 
immunoglobulin G (IgG; DAKO, Glostrup, 
Copenhagen, Denmark). The positive control was a 
section of liposarcoma for MDM2 and colorectal 
carcinoma for B-RAF.  
All sections were assessed and scored. The 
sections were examined by using light microscope 
[Scope A1, Axio, Zeiss, Germany]. Photomicrographs 
were taken using a microscope-camera [AxioCam, 
MRc5, Zeiss, Germany]. All procedures were done at 
the pathology department of Theodor Bilharz 
Research Institute, Cairo, Egypt. 
Scoring of MDM2 immunostaining was 
performed semiquantitatively, using digital images 
and 22-in monitor with hardware calibration 
capabilities. Staining was considered to be negative 
(0) if no staining was seen within a tumour, weakly 
positive (1+) if focal staining was seen, and strongly 
positive (2+) if there was diffuse staining in more 
than 80% of tumour cells [18]. Nuclear staining 
could be detected in very few cases, and the vast 
majority of positive cases showed only cytoplasmic 
staining. 
The intensity of cytoplasmic immunostaining 
was scored from zero to 3 (0: no staining, 1: weak, 2: 
moderate and 3: strong) [19]. Cases with moderate 
and strong immunostaining were considered positive 
[20].  
We have also counted the percentage of cells 
with positive expression in 5 successive high power 
fields. 
The immunohistochemical results were 
analysed using SPSS version 20 (IBM Corporation, 
Armonk, New York, USA). Data are presented as the 
mean ± S.D. Two-tailed Student’s t-tests and one-way 
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ANOVA were used to evaluate the data. Comparison 
of difference in percentage between groups was 
evaluated using two-tailed Fischer's exact test. 
Differences were considered statistically significant at 
P < 0.05. 
 
 
Results 
 
Different studied gastric lesions were more 
common in males (73.5%) than females (26.5%). The 
differences were statistically significant (p < 0.05) in 
cases of chronic gastritis and intestinal GC, while non-
significant in cases of diffuse GC and GIST (p > 0.05) 
(Table 1). 
Table 1: Gender in different studied lesions 
Lesion 
Gender 
Total no. (%) 
Female no. (%) Male no. (%) 
Chronic gastritis 4a (11) 28b (28) 32 (23.5) 
Intestinal GC 24a (66.7) 46b (46) 70 (51.5) 
Diffuse GC 6a (16.7) 16a (16) 22 (16.2) 
GIST 2a (5.6) 10a (10) 12 (8.8) 
Total 36 100 136 
GC: gastric cancer, GIST: gastrointestinal stromal tumor. 
 
Endoscopically, cases of chronic gastritis 
represented usually as diffuse mucosal lesions, cases 
of intestinal and diffuse GC represented as fungating 
or ulcerative lesions and usually located at the gastro-
oesophagal junction (GEJ) or pylorus, while GIST 
cases represented as mass lesions. No significant 
differences were found considering endoscopic 
appearance or location of studied gastric lesions 
(Table 2). 
Table 2: Endoscopic appearance and location of studied 
gastric lesions 
 Lesion  
Chronic 
gastritis 
no. (%) 
Intestinal 
GC 
no. (%) 
Diffuse GC 
no. (%) 
GIST 
 
no. (%) 
Total 
E
n
d
o
s
c
o
p
ic
 
a
p
p
e
a
ra
n
c
e
 Diffuse 32a (100) 0b 0b 0b 32 (23.5) 
Fungating 0a 64b (91.4) 20b (90.9) 0a 84 (61.8) 
Mass 0a 0a 0a 8b (66.7) 8 (5.9) 
Ulcer 0a 6a (8.6) 2a (9.1) 0a 8 (5.9) 
Wall thickening 0a 0a 0a 4b (33.3) 4 (2.9) 
A
n
a
to
m
ic
 s
it
e
 Unavailable  32a (100) 56b, c (80) 14c (63.6) 12a, b(100) 114(83.8) 
Cardia 0a 2a(2.9) 0a 0a 2(1.5) 
Diffuse 0a 2a(2.9) 0a 0a 2(1.5) 
Fundus 0a 4a(5.7) 0a 0a 4(2.9) 
GEJ 0a 4a, b(5.7) 4b(18.2) 0a, b 8(5.9) 
Pylorus 0a 2a(2.9) 4a(18.2) 0a 6(4.4) 
Total  32 70 22 12 136 
GC: gastric cancer, GEJ: gastro-esophageal junction, GIST: gastrointestinal stromal 
tumor. 
 
Cases of intestinal GC and diffuse GC 
showed the significantly higher percentage of H. pylori 
positivity compared to chronic gastritis and GIST (p < 
0.05) (Table 3). 
All studied chronic gastritis and GIST cases 
were negative for MDM2 expression. MDM2 positivity 
was identified in 31.4% of intestinal GC and 9.1% of 
diffuse GC, with the statistically significant difference 
between intestinal GC and other groups (p < 0.001) as 
well as between diffuse GC and both chronic gastritis 
and GIST (p < 0.05).  
Table 3: Association between H. pylori and different studied 
lesions 
 Lesion  
Total 
no. (%) 
H. pylori Chronic gastritis 
no. (%) 
Intestinal GC 
no. (%) 
Diffuse GC 
no. (%) 
GIST 
no. (%) 
Positive 12a (37.5) 44b (62.9) 14a,b(63.6) 6a,b (50) 76 (55.9) 
Negative 20a (62.5) 26b (37.1) 8a,b (36.4) 6a,b (50) 60 (44.1) 
total 32 70 22 12 136 
GC: gastric cancer, GIST: gastrointestinal stromal tumor. 
 
On the other hand, B-RAF positivity was 
identified in all studied GIST cases, 22.9% of intestinal 
GC and 6.2% of chronic gastritis cases, while all 
diffuse GC were negative, with statistically significant 
difference comparing GIST to other groups (p < 0.001) 
and comparing intestinal GC to chronic gastritis and 
diffuse GC (p < 0.05) (Table 4). 
Table 4: MDM2 and B-RAF immunoreactivity in different 
lesions 
 MDM2 B-RAF Total 
Lesion Negative 
no. (%) 
Positive 
no. (%) 
Negative 
no. (%) 
Positive 
no. (%) 
 
Chronic gastritis  32 (100) 0 30 (93.8) 2 32 
Intestinal GC 48 (68.6) 22 (31.4)
**
 54 (77.1) 16 (22.9)
#
 70 
Diffuse GC 20 (90.9) 2 (9.1)
*
 22 (100) 0 22 
GIST 12 (100) 0 0 12 (100)
**
 12 
Total 112 24 106 30 136 
GC: gastric cancer, GIST: GIST: gastrointestinal stromal tumor; 
**
 Significant difference 
with other groups (p < 0.001); 
*
 Significant difference with chronic gastritis and GIST (p < 
0.05); 
#
Significant difference with chronic gastritis and diffuse GC (p < 0.05). 
 
Mean percentage of MDM2 positive cells and 
intensity of expression were significantly higher in 
intestinal GC followed by diffuse GC compared to 
chronic gastritis and GIST cases (p < 0.001), while 
mean percentage of B-RAF positive cells and the 
intensity of expression were significantly higher in 
GIST followed by intestinal GC compared to chronic 
gastritis and diffuse GC cases (p < 0.001) (Table 5). 
Table 5: Expression of MDM2 and B-RAF (mean percentage of 
positive cells and intensity of expression) in different studied 
lesions 
Lesion (no.) Mdm2 B-raf 
Percent Intensity Percent Intensity 
Mean ± Std. Error of mean Mean ± Std. Error of mean 
Chronic gastritis (32) 0.50 ± 0.35 0.06 ± 0.04 2.31 ± 1.32 0.19 ± 0.09 
Intestinal GC (70) 8.51 ± 1.28 0.94 ± 0.08 15.49 ± 3.12 0.74 ± 0.10 
Diffuse GC (22) 1.45 ± 0.70 0.27 ± 0.13 0.00 ± 0.00 0.00 ± 0.00 
GIST (12) 0.00 ± 0.00 0.00 ± 0.00 86.67 ± 1.42 2.67 ± 0.14 
p value P < 0.001 P < 0.001 P < 0.001 P < 0.001 
GC: gastric cancer, GIST: GIST: gastrointestinal stromal tumor. 
 
For statistical purposes, we separately 
studied the relation between clinic-pathological 
features of intestinal GC cases and 
immunohistochemical expression results of MDM2 
and B-RAF. 
As regards the endoscopic appearance of 
intestinal GC; fungating lesions exhibited a higher 
percentage of MDM2 positive cells and MDM2 
intensity of expression, while ulcerative lesions 
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exhibited a higher percentage of B-RAF positive cells 
and B-RAF intensity of expression. However, these 
relations did not reach a significant difference 
between examined groups (p > 0.1) (Table 6).  
Table 6: Relationship between the expression of MDM2 and B-
RAF with the Endoscopic appearance of intestinal GC  
Endoscopic appearance 
(no. Of lesions) 
MDM2 B-RAF 
Percent Intensity Percent Intensity 
Mean ± Std. Error of mean Mean ± Std. Error of mean 
Fungating (64) 8.94 ± 1.38 0.97 ± 0.08 15.38 ± 3.33 0.72 ± 0.10 
Ulcer (6) 4.00 ± 1.26 0.67 ± 0.21 16.67 ± 9.01 1.00 ± 0.37 
P value P > 0.1 P > 0.1 P > 0.1 P > 0.1 
 
Considering the tumour location, the mean 
percentage of MDM2 positive cells and intensity of 
expression were significantly higher in tumours with 
the diffuse location, followed by GEJ compared to 
other sites (p < 0.001). On the other hand, the mean 
percentage of B-RAF positive cells and intensity of 
expression were higher in tumours at GEJ followed by 
fundus compared to other sites; the difference was 
statistically significant for B-RAF intensity score (p < 
0.001) but non-significant for B-RAF per cent (p > 0.1) 
(Table 7).  
Table 7: Relationship between the expression of MDM2 and B-
RAF with anatomical site of intestinal GC  
 
Anatomical site 
(no. Of lesions) 
MDM2 B-RAF 
Percent Intensity Percent Intensity 
Mean ± Std. Error of mean Mean± Std. Error of mean 
Undefined (56) 5.18 ± 0.50 0.79 ± 0.06 14.71 ± 3.51 0.68 ± 0.10 
Cardia (2) 5.00 ± 0.00 1.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Diffuse (2) 40.00 ± 0.00 3.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Fundus (4) 17.50 ± 7.22 1.00 ± 0.00 20.00 ± 11.58 1.00 ± 0.58 
GEJ (4) 29.00 ± 12.12 2.00 ± 0.58 45.00 ± 1443 2.50 ± 0.29 
Pylorus (2) 15.00 ± 0.00 1.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
P value P < 0.001 P < 0.001 P > 0.1 P < 0.001 
GEJ: gastro-oesophageal junction. 
 
Regarding H. pylori association, the mean 
percentage of MDM2 positive cells and intensity of 
expression were higher in H. pylori-associated 
intestinal GC compared to H. pylori non-associated 
tumours, without a statistically significant difference (p 
> 0.1). On the contrary, mean percentage of B-RAF 
positive cells and intensity of expression were higher 
in H. pylori non-associated intestinal GC, without 
statistical significance (p > 0.1) (Table 8). 
Table 8: Relationship between the expression of MDM2 and B-
RAF with H. pylori association of intestinal GC  
H. Pylori 
(no. Of lesions) 
Mdm2 B-raf 
Percent Intensity Percent Intensity 
Mean ± std.error of mean Mean ± std.error of mean 
Positive (44) 9.41 ± 1.85 1.00 ± 0.11 14.55 ± 3.87 0.73 ± 0.13 
Negative (26) 7.00 ± 1 0.85 ± 0.07 17.08 ± 5.36 0.77 ± 0.14 
P value P > 0.1 P > 0.1 P > 0.1 P > 0.1 
 
Mean percentage of MDM2 positive cells and 
intensity of expression were significantly higher in high 
grade intestinal GC compared to low grade ones (p < 
0.0001 & p < 0.01 respectively), and in high stage 
compared to lower stages; the difference was 
statistically significant for MDM2 intensity score (p < 
0.05) and non-significant for MDM2 percent (p > 0.05), 
additionally percentage of MDM2 positive cells and 
intensity of expression increased significantly with 
increasing lymph node stage (p < 0.05 and < 0.0001 
respectively) and with presence of distant metastases; 
the difference was statistically significant for MDM2 
intensity score (p < 0.05) and non-significant for 
MDM2 percent (p > 0.01) (Table 10). 
Table 9: Relationship between the expression of MDM2 and B-
RAF with intestinal GC grade of differentiation 
Grade  
(no. Of lesions) 
MDM2 B-RAF 
Percent Intensity Percent Intensity 
Mean ± Std. Error of mean Mean ± Std. Error of mean 
High (12) 21.83 ± 5.77 1.50 ± 0.34 25.83 ± 8.28 1.17 ± 0.37 
Low (58) 5.76 ± 0.52 0.83 ± 0.05 13.34 ± 3.33 0.66 ± 0.09 
P value P < 0.0001 P < 0.01 P > 0.1 P < 0.05 
 
In addition, mean percentage of B-RAF 
positive cells and the intensity of expression were 
higher in high-grade intestinal GC compared to low-
grade tumours; the difference was statistically 
significant for B-RAF intensity score (p < 0.05) and 
non-significant for B-RAF per cent (p > 0.1) (Table 9), 
moreover, these parameters were higher in T3 
intestinal GC compared to T2 and T4 without 
statistical significance (p > 0.1) (Table 8). Also, B-RAF 
parameters were higher in N1 stage compared to N0 
and N3 and in M0 compared to M1without statistical 
significance (Table 10). 
Table 10: Relationship between the expression of MDM2 and B-
RAF in intestinal GC with TNM stage 
Item (no. Of 
lesions) 
MDM2 B-RAF 
Percent Intensity Percent Intensity 
Mean ± Std. Error of mean Mean ± Std. Error of mean 
T  
2 (12) 2.50 ± 0.75 0.50 ± 0.15 13.83 ± 7.62 0.67 ± 0.22 
3 (38) 9.21 ± 2.08 1.00 ± 0.12 18.84 ± 4.85 0.79 ± 0.13 
4 (20) 10.80 ± 1.76 1.00 ± 0.00 10.10 ± 3.76 0.70 ± 0.18 
P value P > 0.05 P < 0.05 P > 0.1 P > 0.1 
N     
0 (28) 5.14 ± 1.09 0.57 ± 0.10 7.07 ± 3.40 0.50 ± 0.12 
1 (26) 8.15 ± 1.29 1.00 ± 0.00 22.46 ± 5.67 0.92 ± 0.15 
3 (16) 15.00 ± 4.52 1.50 ± 0.22 18.88 ± 7.64 0.88 ± 0.27 
P value P < 0.05 P < 0.0001 P > 0.05 P > 0.1 
M     
0 (52) 8.04 ± 1.47 0.85 ± 0.08 17.00 ± 3.67 0.85 ± 0.12 
1 (18) 9.89 ± 2.60 1.22 ± 0.15 11.11 ± 5.95 0.44 ± 0.12 
P value P > 0.1 P < 0.05 P > 0.1 P > 0.05 
 
Each subscript letter denotes a subset of 
gender categories whose column proportions do not 
differ significantly from each other at the 0.05 level. 
Each subscript letter denotes a subset of 
lesion categories whose column proportions do not 
differ significantly from each other at the 0.05 level 
Each subscript letter denotes a subset of 
lesion categories whose column proportions do not 
differ significantly from each other at the 0.05 level. 
 
 
Discussion 
 
Gastric cancer is still a serious public health 
problem in the world. The high mortality rate that is 
seen globally is mainly due to the advanced stage at 
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diagnosis with the availability of few biomarkers for 
early detection [21]. 
 
Figure 1: Sections from gastric tissue showing: A) A case of chronic 
gastritis (H&E stain X200); B) Helicobacter pylori microorganisms in 
relation to surface epithelium of gastric mucosa (arrows) (Giemsa 
stain X 400); C) A case of intestinal type gastric adenocarcinoma of 
low grade (H & E stain X 200); D) A case of high-grade gastric 
adenocarcinoma; intestinal type (H & E stain, X 200); E) A case of 
diffuse gastric carcinoma of signet-ring type (H & E stain X 200) 
 
In the present work, male predominance was 
reported which is similar to the worldwide trend (2:1) 
[22], as 73.5% of gastric lesions belonged to males 
compared to 26% belonged to females, with incidence 
2.8:1. A percentage lower than ours reported by 
Gaballah et al., [23] and Darwish et al., [24] who 
reported male to female ratio of 1.2:1 and 1.3: 1 
respectively.  
 
Figure 2: IHC using anti-MDM-2 monoclonal antibody in gastric 
sections: A) A case of chronic gastritis negative for MDM2 
expression (X 200); B) A case of chronic gastritis with intestinal 
metaplasia negative for MDM2 (X 200); C) Sections in intestinal-
type gastric carcinoma, low grade, showing mild focal nuclear 
expression of MDM2 (X 100); D) Section in intestinal-type gastric 
carcinoma, high grade, showing mild focal expression of MDM2 (X 
200); E) Section in signet-ring type gastric carcinoma, negative for 
MDM2 expression (X 100) 
 
The International Agency for Research on 
Cancer (IARC) classified H. pylori bacterium as a 
Group I carcinogen [25] H. pylori is a pathogen that 
colonises the gastric epithelium and causes chronic 
inflammation and considerably increases the risk of 
developing GC [26]. Our study showed that H. pylori 
were significantly associated with intestinal-type and 
diffuse GCs compared to GISTs and chronic gastritis, 
this comes by previous reports [27] [28] [29].  
Endoscopically, our studied data sheet 
showed that cases of chronic gastritis usually 
represented as diffuse mucosal lesions, cases of 
intestinal and diffuse GC represented as fungating or 
ulcerative lesions, while GIST cases represented as 
mass lesions. Anatomically, no significant difference 
was detected considering the location of studied 
gastric lesions. Anatomical site of most of our studied 
lesions had not been mentioned. However, GEJ was 
the most frequent site mentioned for GCs; and this 
could be related to gastro-oesophageal reflux. 
 
Figure (3): IHC using anti-B-RAF monoclonal antibody in gastric 
sections expressed as brown cytoplasmic staining (X 200): A) A 
case of chronic gastritis showing negative B-RAF expression (X 
200); B) A case of intestinal type gastric adenocarcinoma, low 
grade, showing mild focal B-RAF expression (X 200); C) & D) 
Sections in intestinal-type gastric adenocarcinoma, high grade, 
showing moderate B-RAF expression (X 200); E) A case of diffuse 
gastric carcinoma (signet ring pattern) showing negative B-RAF 
expression (X 200); F) A case of gastrointestinal stromal tumour 
(GIST) showing moderate B-RAF expression (X200) 
 
Wade et al., [30] and Li and Lozano [10] 
reported that MDM2 oncogene played an important 
role in cancer progression and MDM2 overexpression 
in tumour cells induced cell proliferation inhibited cell 
apoptosis. We found MDM2 positivity in 31.4% of 
intestinal GC cases. Gunther et al., [31] found MDM2 
expression in 45% of intestinal GCs. However, Ye et 
al., [32] reported a much higher per cent, as they 
detected MDM2 immunopositivity in 70.4% of their GC 
cases. Moreover, intestinal GC exhibited a 
significantly higher percentage of MDM2 positive cells 
(8.51%) and higher intensity of expression compared 
to other groups. This matches the findings of Gunther 
et al., [31] and Nakajima [33] who detected MDM2 
positivity in 10% and 7.76% of gastric cancer cells 
respectively. Shen et al., [34] stated that MDM2 
expressed at higher levels in GC tissues than in non-
cancerous gastric mucosa. On the contrary, Busuttil et 
al., [21] observed negligible levels of MDM2 staining 
in GC samples. Variable results between studies may 
be attributed to different risk factors promoting to 
gastric cancer including H. pylori, obesity, tobacco 
smoking, red meat, a high-salt diet, alcohol, and low 
socioeconomic status, genetic polymorphisms, the 
age of cancer onset and gender.  
On the other hand, B-RAF was expressed in 
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all GIST specimens that showed a significantly higher 
mean percentage of B-RAF positive cells (86.67%) 
and higher intensity of expression compared to other 
groups. This matches with findings of Holstein et al., 
[35] who observed B-RAF expression in all GIST 
cases in more than 80% of cells. On the contrary, 
several other studies reported a much smaller 
percentage of B-RAF positivity in GIST than ours [36] 
[37] [38] as they detected B-RAF mutation in 7%, 
3.8% and 3.5% of GISTs respectively. Furthermore, 
intestinal GC cases showed significantly higher 
expression of B-RAF (higher number of positive 
cases, the percentage of positive cells and intensity of 
expression) compared to chronic gastritis and diffuse 
GC. Many previous studies reported the presence of a 
B-RAF mutation in patients with gastric 
adenocarcinoma [27] [39] [40].  
Considering cases of intestinal type GC, no 
statistically significant difference was achieved when 
comparing fungating and ulcerating intestinal GC for 
parameters of MDM2 and B-RAF expression (mean 
percentage of positive cells and intensity of 
expression). Tumours with diffuse location and at GEJ 
showed significantly higher mean percentage of 
MDM2 positive cells and MDM2 intensity of 
expression. On the other hand, tumours at GEJ and 
fundus showed non-significantly higher mean 
percentage of B-RAF positive cells and significantly 
higher B-RAF intensity of expression. To our 
knowledge, no other studies demonstrated MDM2 or 
B-RAF expression about endoscopic appearance or 
anatomical site of intestinal GC.  
In the present study, MDM2 parameters were 
non-significantly higher in H. pylori-associated 
intestinal GC than in H. pylori non-associated ones. 
This goes with many previous studies reporting that H. 
pylori infection was associated with higher expression 
of MDM2 in intestinal metaplasia and gastric 
carcinoma [33] [41] [42]. Furthermore, Kodama et al., 
[43] reported that successful eradication of H. pylori 
dramatically reduced MDM2 levels. On the contrary, 
B-RAF parameters were non-significantly higher in H. 
pylori-non-associated intestinal GC than in H. pylori-
associated ones; however, Sabry et al., [27] found a 
significant positive relationship between the qPCR of 
H. pylori and quantitative B-RAF in GC cases.  
As regards different grades of differentiation 
in intestinal GC, we found a statistically significant 
higher percentage of MDM2 positive cells and non-
significant higher percentage of B-RAF positive cells 
in high-grade tumours compared to low-grade ones. 
This goes with findings of Sabry et al., [27] who 
detected a significant positive correlation between 
grades of GC and qPCR of B-RAF. 
Our current results showed an increase in 
MDM2 expression parameters with increasing depth 
of invasion, the presence of distant metastases and 
lymph node metastases. This matches with Ye et al., 
[32] results which reported that MDM2 expression was 
associated with depth of invasion, lymph node 
metastases and distant metastases. Sepideh et al., 
[44] found a direct correlation between lymph node 
metastases and MDM2 staining intensity; meanwhile, 
they did not find a remarkable correlation between 
MDM2 expression and nodal involvement.  
As regards B-RAF expression parameters in 
intestinal GC, no significant differences were achieved 
with different tumour stages, different stages of lymph 
node metastasis and state of distant metastases. 
These findings match results of other previous studies 
which did not find a relationship between B-RAF 
expression and histopathological variables of GC [45] 
[46] [47].  
In conclusion, we found that: (1) MDM2 up-
regulation was more frequent in intestinal GC 
compared to other groups, while B-RAF up-regulation 
was more frequent in GIST compared to other groups; 
(2) H. pylori induces MDM2 up-regulation in intestinal 
GC; (3) In intestinal GC cases, MDM2 expression was 
correlated with high grade of differentiation, deep 
invasion, nodal and distant metastases, meanwhile, 
B-RAF expression was correlated with high-grade 
tumours but had no association with TNM stage. The 
possible role of both MDM2 and B-RAF in predicting 
progression of gastric tumours and prognosis 
deserves further investigations. 
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